The high molecular weight adiponectin level is associated with the atherogenic lipoprotein profiles in healthy Japanese males

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 7, 2014, Pages 672-679

  Miyazaki, Tetsuro ^a   Hiki, Makoto ^a   Shimada, Kazunori ^a   Kume, Atsumi ^a   Kiyanagi, Takashi ^a   Sumiyoshi, Katsuhiko ^a   Ohmura, Hirotoshi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherogenic lipoprotein; High molecular weight adiponectin; Metabolic syndrome; Small HDL; Small LDL

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; LIPOPROTEIN;

ATHEROSCLEROSIS; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; PATHOLOGY; PROGNOSIS;

ADIPONECTIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; PROGNOSIS;

EID: 84905190339     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.22152     Document Type: Article

References (35)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to c1q, produced exclusively in adipocytes. J Biol Chem, 1995; 270: 26746-26749
2. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: Cdna cloning and expression of a novel adipose specific collagen-like factor, apm1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun, 1996; 221: 286-289
3. Shimada K, Miyazaki T, Daida H: Adiponectin and atherosclerotic disease. Clin Chim Acta, 2004; 344: 1-12
4. Lara-Castro C, Fu Y, Chung BH, Garvey WT: Adiponectin and the metabolic syndrome: Mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol, 2007; 18: 263-270
5. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, Hoo RC, Mak WW, Cooper GJ, Xu A: Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem, 2006; 281: 16391-16400
6. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care, 2006; 29: 1357-1362
7. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, Aso Y, Inukai T, Okuno T, Node K: High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol, 2007; 100: 569-574
8. Liu Y, Retnakaran R, Hanley A, Tungtrongchit R, Shaw C, Sweeney G: Total and high molecular weight (hmw) but not trimeric or hexameric forms of adiponectin correlate with markers of the metabolic syndrome and liver injury in thai subjects. J Clin Endocrinol Metab, 2007
9. Seino Y, Hirose H, Saito I, Itoh H: High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in japanese men. Metabolism, 2007; 56: 1493-1499
10. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I: Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb, 2010; 17: 1201-1211
11. Basu R, Pajvani UB, Rizza RA, Scherer PE: Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: Differential regulation from nondiabetic subjects. Diabetes, 2007; 56: 2174-2177
12. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y: Comparison of serum high-molecular weight (hmw) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect hmw adiponectin. Diabetes, 2006; 55: 1954-1960
13. Saito I, Yamagishi K, Chei CL, Cui R, Ohira T, Kitamura A, Kiyama M, Imano H, Okada T, Kato T, Hitsumoto S, Ishikawa Y, Tanigawa T, Iso H: Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. Atherosclerosis, 2013; 229: 222-227
14. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB: Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis, 2011; 219: 322-329
15. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: Ncep-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among nhanes iii participants age 50 years and older. Diabetes, 2003; 52: 1210-1214
16. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of scotland coronary prevention study. Circulation, 2003; 108: 414-419
17. Kasai T, Miyauchi K, Kurata T, Ohta H, Okazaki S, Miyazaki T, Kajimoto K, Kubota N, Daida H: Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J, 2006; 70: 1531-1537
18. Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol, 2002; 90: 22i-29i
19. Miyazaki T, Shimada K, Sato O, Kotani K, Kume A, Sumiyoshi K, Sato Y, Ohmura H, Watanabe Y, Mokuno H, Daida H: Circulating malondialdehyde-modified ldl and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis, 2005; 179: 139-145
20. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia, 2003; 46: 459-469
21. Okada T, Saito E, Kuromori Y, Miyashita M, Iwata F, Hara M, Harada K: Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children. Atherosclerosis, 2006; 188: 179-183
22. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 2006; 55: 249-259
23. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome--a new worldwide definition. Lancet, 2005; 366: 1059-1062
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412-419
25. Katsuki A, Suematsu M, Gabazza EC, Murashima S, Nakatani K, Togashi K, Yano Y, Sumida Y: Decreased high-molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care, 2006; 29: 2327-2328
26. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by hplc. J Lipid Res, 2002; 43: 805-814
27. Miyazaki T, Shimada K, Miyauchi K, Kume A, Tanimoto K, Kiyanagi T, Sumiyoshi K, Hiki M, Mokuno H, Okazaki S, Sato H, Kurata T, Daida H: Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and instent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis, 2010; 9: 122
28. Matsumori R, Miyazaki T, Shimada K, Kume A, Kitamura Y, Oshida K, Yanagisawa N, Kiyanagi T, Hiki M, Fukao K, Hirose K, Ohsaka H, Mokuno H, Daida H: High levels of very long-chain saturated fatty acid in erythrocytes correlates with atherogenic lipoprotein profiles in subjects with metabolic syndrome. Diabetes Res Clin Pract, 2013; 99: 12-18
29. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesteryl ester transfer protein: A novel target for raising hdl and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol, 2003; 23: 160-167
30. Qiao L, Zou C, van der Westhuyzen DR, Shao J: Adiponectin reduces plasma triglyceride by increasing vldl triglyceride catabolism. Diabetes, 2008; 57: 1824-1833
31. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA: Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care, 2005; 28: 2181-2186
32. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA, Investigators C: The effect of atorvastatin on serum lipids, lipoproteins and nmr spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis, 2003; 167: 243-255
33. Kwiterovich PO Jr: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol, 2002; 90: 30i-47i
34. Tsubakio-Yamamoto K, Matsuura F, Koseki M, Oku H, Sandoval JC, Inagaki M, Nakatani K, Nakaoka H, Kawase R, Yuasa-Kawase M, Masuda D, Ohama T, Maeda N, Nakagawa-Toyama Y, Ishigami M, et al: Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun, 2008; 375: 390-394
35. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y: Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis, 2009; 202: 152-161